Natera Appoints Oncology Experts Thomas Lynch and Eric Rubin to Board of Directors
Natera Appoints Oncology Leaders Thomas Lynch and Eric Rubin to Board of Directors to Strengthen Precision Medicine Strategy Natera, Inc., a global leader in cell-free DNA testing and precision medicine…
New Evidence Supports Ketogenic Therapy Potential in Anorexia Nervosa Treatment
New Evidence Supports Ketogenic Therapy as a Potential Treatment for Anorexia Nervosa A pilot clinical study published in Communications Medicine has reported promising early evidence that a ketogenic nutritional intervention…
DocGo Expands Mobile Phlebotomy Services into South Florida
DocGo Expands PTI Health Mobile Phlebotomy Services Into Southern Florida Through Expanded Laboratory Partnership DocGo Inc., a leading provider of technology-enabled mobile health services and medical transportation solutions, has announced…
Terremoto Biosciences Receives FDA Fast Track for TER-2013 AKT1-Selective Inhibitor in Breast Cancer
Terremoto Biosciences Receives FDA Fast Track Designation for TER-2013 in Advanced HR+/HER2- Breast Cancer Terremoto Biosciences, a biotechnology company focused on developing highly targeted small-molecule therapies for cancer, has announced…
Niagen Bioscience Rebrands Research Initiative as Niagen Research Program
Niagen Bioscience Renames Research Program to Strengthen Global Commitment to NAD+ Science and Healthy Aging Research Niagen Bioscience, Inc. (NASDAQ: NAGE), a company focused on advancing the science of healthy…
Gilead’s Livdelzi Achieves Significant ALP Normalization in Phase 3 IDEAL Trial for Primary Biliary Cholangitis
Gilead Reports Positive Phase 3 Results for Livdelzi in Primary Biliary Cholangitis, Demonstrating Significant Improvement in Liver Disease Marker Gilead Sciences has announced positive topline results from the Phase 3…
Moonlight Therapeutics Launches Phase I SURVEYOR Trial of MOON101 for Peanut Allergy
Moonlight Therapeutics Launches First-in-Human Phase I Trial of MOON101 for Peanut Allergy Moonlight Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for food allergies, has announced the…
Alliance Clinical Network and Atlas Clinical Research Merge to Strengthen Clinical Research Capabilities
Alliance Clinical Network and Atlas Clinical Research Complete Merger to Create Expanded National Clinical Research Platform Alliance Clinical Network and Atlas Clinical Research have announced the successful completion of a…
Camizestrant Combination Cuts Risk of Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 Trial
Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6…
Iza-Bren Significantly Improves Survival Outcomes in TNBC and Esophageal Cancer
Iza-Bren Significantly Improves Overall and Progression-Free Survival in Triple-Negative Breast Cancer and Esophageal Cancer SystImmune, Inc., a clinical-stage biotechnology company focused on developing innovative cancer therapies, and Bristol Myers Squibb…
Hims & Hers Acquires Eucalyptus to Expand Clinically Supported Weight Management Services in Germany
Hims & Hers Completes Acquisition of Eucalyptus, Strengthening Clinically Supported Weight Management Services in Germany Hims & Hers Health, Inc. has officially completed its acquisition of Eucalyptus, the parent company…
Incyte frontMIND Trial Shows Tafasitamab Combo Improves PFS in High-Risk DLBCL
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal…